APA (7th ed.) Citation

Subbiah, V., Makker, V., Oh, D., Gardener, E., Gartner, E., & Meric-Bernstam, F. (2026). DiscovHER PAN-206: Phase 2 tumour-agnostic study of Zanidatamab in patients with previously treated human epidermal growth factor receptor 2 (HER2)-overexpressing solid tumours. Gynecologic Oncology, 208, S144. https://doi.org/10.1016/j.ygyno.2026.01.286

Chicago Style (17th ed.) Citation

Subbiah, Vivek, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, and Funda Meric-Bernstam. "DiscovHER PAN-206: Phase 2 Tumour-agnostic Study of Zanidatamab in Patients with Previously Treated Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing Solid Tumours." Gynecologic Oncology 208 (2026): S144. https://doi.org/10.1016/j.ygyno.2026.01.286.

MLA (9th ed.) Citation

Subbiah, Vivek, et al. "DiscovHER PAN-206: Phase 2 Tumour-agnostic Study of Zanidatamab in Patients with Previously Treated Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing Solid Tumours." Gynecologic Oncology, vol. 208, 2026, p. S144, https://doi.org/10.1016/j.ygyno.2026.01.286.